CRT 2026

Panel Discussion | From EFS to Real World Data

Moderator(s)

• 

  Mitchell Krucoff, MD, FACC, FAHA, FSCAI

  Professor Medicine/Cardiology
  Duke University Medical Center/Duke Clinical Research Institute
  Durham, North Carolina, United States

  Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Nipro Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Shockwave/Johnson&Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Terumo Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
• 

  Andrew Farb, MD

  Chief Medical Officer, Office of Cardiovascular Devices
  U.S. Food and Drug Administration
  Silver Spring, Maryland, United States

  Disclosure information not submitted.

Panel Discussant(s)

• 

  Joaquin E. Cigarroa, MD

  Director, Knight Cardiovascular Institute
  OHSU Knight Cardiovascular Institute
  Portland, Oregon, United States

  Disclosure(s): No financial relationships to disclose
• 

  C. Michael Gibson, MD

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure(s): Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)
• 

  Tamara Syrek Jensen, JD

  Consultant
  Rubrum Advising

  Disclosure(s): No financial relationships to disclose
• 

  Misti Malone, PhD

  Assistant Director, Office of Cardiovascular Devices
  FDA
  Silver Spring, Maryland, United States

  Disclosure(s): No financial relationships to disclose
• 

  Ernest Spitzer, MD

  Chief Executive Officer
  Cardialysis B.V.
  Rotterdam, Zuid-Holland, Netherlands

  Disclosure(s): Abbott Vascular: Grant/Research Support (Ongoing); Biosensors Europe: Grant/Research Support (Ongoing); Boston Scientific Corporation: Grant/Research Support (Ongoing); Edward Lifesciences: Grant/Research Support (Ongoing); Medtronic Inc: Grant/Research Support (Ongoing); Novo Nordisk A/S: Grant/Research Support (Ongoing); Philips Medical: Grant/Research Support (Ongoing); Pie Medical Imaging: Grant/Research Support (Ongoing); Siemens Healthineers AG: Grant/Research Support (Ongoing)
• 

  Rebecca Torguson, MPH

  Division Director
  FDA
  Silver Spring, Maryland, United States

  Disclosure information not submitted.
• 

  Eric Vang, PhD, MPH

  Vice President, Clinical, Medical Affairs & HEPR, Surgical OU
  Medtronic, Inc
  Mounds View, Minnesota, United States

  Disclosure(s): No financial relationships to disclose
• 

  Robert W. Yeh, MD, MSc

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure(s): Abbott Vascular, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CathWorks: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Life Sciences: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Elixir Medical Corporation: Consulting Fees (e.g., advisory boards) (Ongoing)